List view / Grid view
Explore cutting-edge neuroscience insights through an exclusive interview with Dr Olga Chechneva on nuclear interactions in the mouse brain and a groundbreaking study by MIT researchers revealing key aspects of Alzheimer's disease. Download your FREE eBook!
Dr Nicolas Camper at CDMO Abzena and colleagues offer insight into the landscape of antibody-drug conjugates and how the therapy is evolving.
Artificial intelligence (AI) and machine learning (ML) have been gaining significant attention lately, primarily in discussions about their responsible utilisation. However, these technologies possess a wide spectrum of practical applications, ranging from predicting natural disasters to addressing social disparities. Now, AI is making its mark in the field of cancer…
Torsten Müller from Bruker Daltonics shares how trapped ion mobility spectrometry (TIMS) fundamentally improves immunopeptidomics research and addresses key challenges in this rapidly expanding field.
This September edition of our Women in Stem series spotlights Dr Emily Leproust, CEO of Twist Bioscience. Dr Leproust began her STEM journey from a background in chemistry, eventually leading her to the forefront of DNA synthesis technology. She co-founded Twist Bioscience in 2013, now a thriving company reporting substantial…
Human derived induced pluripotent stem cells (hiPSCs) have revolutionised research and are increasingly used for toxicology screening and disease modelling. Early detection of neurotoxicity induced by potential new therapies is a major challenge, and hiPSC-neuronal cells may provide a solution. These cells demonstrate considerable promise for uncovering drug-induced perturbations to…
Organoids, lab-grown 3D structures that mimic human organs, are redefining preclinical research through bypassing the ethical and practical limitations of animal models. Technological advancements in organoid research, including automation and improved analytical tools, promise to unlock new possibilities by streamlining the application of these 3D structures to enhance drug development…
![In experiments in rats and mice, two Johns Hopkins scientists -- an engineer and an ophthalmologist -- report the successful use of nanoparticles to deliver gene therapy for blinding eye disease. A uniquely engineered large molecule allows researchers to compact large bundles of therapeutic DNA to be delivered into the cells of the eye [credit: John Hopkins Medicine].](https://www.drugtargetreview.com/wp-content/uploads/nanoparticle-gene-therapy-blindness-image.jpg)
This article discusses the need for adulticidal drugs to treat Onchocerca volvulus infections, a parasite causing onchocerciasis (river blindness), as the current treatment with ivermectin and surgery presents challenges for affected communities. It highlights research findings on the potential of analgesic medicines to target adult worms and emphasises the importance…
Rob Scoffin and Matthew Habgood from solutions provider Cresset look to the future of drug discovery and the roles that artificial intelligence and machine learning could play.
Recent regulatory changes in the US and Europe are driving the adoption of advanced 3D cell-based technologies, such as organoids and organ-on-chips, in drug development, replacing traditional animal testing and offering safer, cost-effective alternatives.
A group of researchers from Tokyo Metropolitan University have illuminated a crucial piece of the intricate puzzle surrounding the regulation of muscle mass and metabolic processes within skeletal muscle.
A new Drug Target Review issue is now ready to download! This issue features articles on vaccine development, artificial intelligence and organoids.
Scientists at Stanford University have engineered a biomolecule that can specifically remove mucins from cancer cells. This breakthrough could have a significant impact on future cancer therapies.
New research shows T cells use the nuclear receptor RARα not just for gene regulation, but also to trigger cell surface events that activate them against pathogens and cancer.
BlueSphere Bio's TCXpress platform revolutionises the isolation and functional characterisation of T-cell receptors (TCRs) with unparalleled speed and efficiency, enabling rapid identification of unique TCRs from thousands of individual T cells within days.
